According to a recent LinkedIn post from Okami Medical, interventional radiologist Dr. Ahmad Hashmi used the company’s LOBO-9 device in an 86-year-old patient with splenic trauma and reportedly achieved rapid vessel occlusion via a guide catheter. The post notes that no additional embolic devices were required in this specific case.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights LOBO as part of a broader trend toward faster, more efficient embolization in trauma management, a clinically important and economically relevant area for hospitals. For investors, the case example suggests potential for growing adoption of LOBO in high-acuity settings, which could support revenue growth and strengthen Okami Medical’s competitive position in the interventional radiology and MedTech markets.

